{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:45:09Z","timestamp":1768455909257,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.intimp.2024.112192","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:35:18Z","timestamp":1715949318000},"page":"112192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up"],"prefix":"10.1016","volume":"134","author":[{"given":"Mohammadreza","family":"Salehi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilad","family":"Alavi Darazam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Nematollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedigheh","family":"Pouya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasim","family":"Khajavirad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-4597","authenticated-orcid":false,"given":"Meysam","family":"Porgoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosslim","family":"Sedghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Mahdi Sepahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2368-6749","authenticated-orcid":false,"given":"Hamed","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed","family":"Mahmoud Hashemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somaye","family":"Dehghanizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-624X","authenticated-orcid":false,"given":"Vahid","family":"Khoddami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10223","key":"10.1016\/j.intimp.2024.112192_b0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.112192_b0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","article-title":"A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine","volume":"7","author":"Low","year":"2022","journal-title":"npj Vaccines"},{"issue":"4","key":"10.1016\/j.intimp.2024.112192_b0015","doi-asserted-by":"crossref","first-page":"E143","DOI":"10.1503\/cmaj.221068","article-title":"Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19-related deaths among people with multimorbidity: a cohort study","volume":"195","author":"Lai","year":"2023","journal-title":"CMAJ"},{"key":"10.1016\/j.intimp.2024.112192_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105556","article-title":"Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta\/Omicron variants following an inactivated whole-virus vaccine","volume":"212","author":"Lu","year":"2023","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2024.112192_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2022.100211","article-title":"Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents","volume":"12","author":"Puthanakit","year":"2022","journal-title":"Vaccine x."},{"issue":"6","key":"10.1016\/j.intimp.2024.112192_b0030","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jinf.2023.03.027","article-title":"Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines","volume":"86","author":"Shaw","year":"2023","journal-title":"J Infect."},{"issue":"1","key":"10.1016\/j.intimp.2024.112192_b0035","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-022-30340-5","article-title":"Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant","volume":"13","author":"Zuo","year":"2022","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2024.112192_b0040","article-title":"Heterologous inactivated virus\/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1","volume":"33","author":"Zuo","year":"2023","journal-title":"Lancet Reg Health West Pac."},{"issue":"1","key":"10.1016\/j.intimp.2024.112192_b0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14760584.2024.2320861","article-title":"Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine","volume":"23","author":"Luvira","year":"2024","journal-title":"Expert Rev Vaccines."},{"issue":"10324","key":"10.1016\/j.intimp.2024.112192_b0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2024.112192_b0055","doi-asserted-by":"crossref","first-page":"541 e1","DOI":"10.1016\/j.cmi.2022.11.017","article-title":"Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile","volume":"29","author":"Acevedo","year":"2023","journal-title":"Clin Microbiol Infect."},{"issue":"8","key":"10.1016\/j.intimp.2024.112192_b0060","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/infdis\/jiac092","article-title":"Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination","volume":"226","author":"Assawakosri","year":"2022","journal-title":"J Infect Dis."},{"issue":"12","key":"10.1016\/j.intimp.2024.112192_b0065","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.vaccine.2023.01.032","article-title":"Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals","volume":"41","author":"Mallah","year":"2023","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.intimp.2024.112192_b0070","doi-asserted-by":"crossref","first-page":"e1010022","DOI":"10.1371\/journal.ppat.1010022","article-title":"Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination","volume":"17","author":"Davis","year":"2021","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.intimp.2024.112192_b0075","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.112192_b0080","article-title":"Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine","volume":"2","author":"Yigit","year":"2022","journal-title":"J Clin Virol plus."},{"issue":"27","key":"10.1016\/j.intimp.2024.112192_b0085","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112192_b0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112192_b0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41541-022-00528-3","article-title":"SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN((R)), induces robust humoral and cellular immunity in mice and non-human primates","volume":"7","author":"Alimohammadi","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.intimp.2024.112192_b0100","unstructured":"Administration FaD. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials 2007 [Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical]."},{"issue":"12","key":"10.1016\/j.intimp.2024.112192_b0105","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1016\/S1473-3099(23)00682-5","article-title":"Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1","volume":"23","author":"Lassauniere","year":"2023","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"10.1016\/j.intimp.2024.112192_b0110","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","article-title":"Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure","volume":"24","author":"Yang","year":"2024","journal-title":"Lancet Infect Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.112192_b0115","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/14760584.2023.2232851","article-title":"Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era","volume":"22","author":"Pather","year":"2023","journal-title":"Expert Rev Vaccines."},{"issue":"46","key":"10.1016\/j.intimp.2024.112192_b0120","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1016\/j.vaccine.2022.09.082","article-title":"Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil","volume":"40","author":"Ferreira","year":"2022","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2024.112192_b0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41577-022-00687-3","article-title":"Modelling vaccination strategies for COVID-19","volume":"22","author":"Wagner","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112192_b0130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41422-022-00626-w","article-title":"Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant","volume":"32","author":"Zhang","year":"2022","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.intimp.2024.112192_b0135","doi-asserted-by":"crossref","first-page":"e10060","DOI":"10.1002\/amp2.10060","article-title":"Rapid development and deployment of high-volume vaccines for pandemic response","volume":"2","author":"Kis","year":"2020","journal-title":"J Adv Manuf Process."},{"key":"10.1016\/j.intimp.2024.112192_b0140","unstructured":"[Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/stay-up-to-date.html]."},{"issue":"1","key":"10.1016\/j.intimp.2024.112192_b0145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12879-023-08079-1","article-title":"Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18\u201370 years","volume":"23","author":"Gholami","year":"2023","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.intimp.2024.112192_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2023.09.027","article-title":"Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18\u201370 Years; A Randomized, Double-Blind Clinical Trial","author":"Mohazzab","year":"2023","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.intimp.2024.112192_b0155","doi-asserted-by":"crossref","first-page":"e070464","DOI":"10.1136\/bmj-2023-070464","article-title":"Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial","volume":"382","author":"Mohraz","year":"2023","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.intimp.2024.112192_b0160","doi-asserted-by":"crossref","first-page":"e2310302","DOI":"10.1001\/jamanetworkopen.2023.10302","article-title":"Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial","volume":"6","author":"Mostafavi","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"2","key":"10.1016\/j.intimp.2024.112192_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28097","article-title":"RETRACTED: Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial","volume":"95","author":"Salimian","year":"2023","journal-title":"J Med Virol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112192_b0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2023","journal-title":"Clin Microbiol Infect."},{"issue":"7830","key":"10.1016\/j.intimp.2024.112192_b0175","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"7830","key":"10.1016\/j.intimp.2024.112192_b0180","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.intimp.2024.112192_b0185","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112192_b0190","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.intimp.2024.112192_b0195","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14760584.2023.2209177","article-title":"Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review","volume":"22","author":"Shabu","year":"2023","journal-title":"Expert Rev. Vaccines"},{"issue":"4","key":"10.1016\/j.intimp.2024.112192_b0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.33160\/yam.2021.11.003","article-title":"Physical Characteristics of Injection Site Pain After COVID-19 mRNA BNT162b2 Vaccination","volume":"64","author":"Tomita","year":"2021","journal-title":"Yonago Acta Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112192_b0205","article-title":"COVID-19 mRNA Vaccines: The Molecular Basis of Some Adverse Events","volume":"11","author":"Giannotta","year":"2023","journal-title":"Vaccines (basel)"},{"issue":"17\u201318","key":"10.1016\/j.intimp.2024.112192_b0210","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","article-title":"Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial","volume":"133","author":"Kremsner","year":"2021","journal-title":"Wien Klin Wochenschr."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T14:03:48Z","timestamp":1735308228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924007100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":42,"alternative-id":["S1567576924007100"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112192","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112192"}}